Europe
Karolinska Development’s portfolio company Modus Therapeutics announces that the first cohort has been successfully dosed in its
Planegg Medigene AG announced its participation at the following upcoming scientific conferences
Two-year follow-up data shows 100 percent overall survival and 100 percent event free survival in comparison to a historical standard of care from a historical control group.
3BP will employ its high-diversity peptide library and hit identification technology on a set of molecular disease targets selected by Boehringer Ingelheim.
The Vycellix team, which will initially include its senior executive and administrative staff, is scheduled to occupy the new space adjacent to the Moffitt Cancer Center in April.
FINCH 2 Phase 3 trial with filgotinib in rheumatoid arthritis (RA) met all primary and secondary endpoints, with consistent tolerability
Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. announced an agreement to apply Insilico’s technology for predictive biomanufacturing to create and implement more efficient production processes of Teva’s biopharmaceutical therapeutics.
Recipharm announced the intention to end operations in Ashton-under-Lyne, United Kingdom
Research is the cornerstone of new medications that treat numerous needs across the globe. Here’s a look at a few of the interesting research stories that crossed BioSpace’s slice of the Internet.
Companies make leadership changes to executive teams, including additions at Allergan, Surmodics, Arix, RedHill, Cerevel, Enzyvant, and more.
PRESS RELEASES